XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 36,567,420 $ 65,813,297
Short-term investments 14,235,770 28,300,232
Accounts receivable from affiliated entity 978,590 1,199,056
Prepaid expenses and other current assets 3,398,534 2,517,465
Total current assets 55,180,314 97,830,050
Fixed assets, net 2,740,356 3,659,818
Investments in affiliated entity 2,495,730 1,613,844
Operating lease right-of-use assets 6,956,780 8,113,840
Other assets 2,012,476 1,979,654
Total assets 69,385,656 113,197,206
Current liabilities:    
Accrued clinical trial expenses 955,970 2,021,860
Common stock warrant liabilities 50,384,043 13,255,188
Operating lease liability 2,738,490 2,497,360
Grant funding liability from affiliated entity 42,152 0
Total current liabilities 69,823,896 35,325,584
Operating lease liability, net of current portion 7,281,737 9,367,827
Total liabilities 77,105,633 44,693,411
Stockholders’ equity:    
Preferred stock 0 0
Common stock 53,572 36,099
Additional paid-in capital 1,811,803,850 1,799,362,625
Accumulated deficit (1,818,930,043) (1,730,219,262)
Accumulated other comprehensive loss (647,356) (675,667)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity (7,719,977) 68,503,795
Total liabilities and stockholders’ equity 69,385,656 113,197,206
Nonrelated Party    
Current liabilities:    
Accounts payable and accrued expenses 15,323,520 16,200,013
Related Party    
Current liabilities:    
Accounts payable and accrued expenses $ 379,721 $ 1,351,163